Stocksigma LogoStocksigma Logo

Hikal Reports Q2 FY27 Revenue Growth of 36% YoY With Stronger Operating Margins

Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY, driven by a 47% YoY growth in Pharmaceuticals to ₹278 crore and a 21% YoY rise

Hikal Reports Q2 FY27 Revenue Growth of 36% YoY With Stronger Operating Margins

Hikal Ltd · Investor Presentation · 03 Nov 2026, 9:39 pm

Hikal Reports Q2 FY27 Revenue Growth of 36% YoY With Stronger Operating Margins Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY, driven by a 47% YoY growth in Pharmaceuticals to ₹278 crore and a 21% YoY rise in Crop Protection to ₹156 crore. EBITDA surged 524% YoY to ₹45 crore, expanding margins by 808 bps YoY to 10.3%. Net loss narrowed to ₹6 crore from ₹35 crore in Q2 FY26. For H1 FY27, revenue rose 20% YoY to ₹837 crore, while EBITDA reached ₹82 crore. Management reiterated full-year guidance of mid-teens revenue growth and substantial profitability improvement.

Original exchange filing (PDF)

More announcements from Hikal Ltd

All Hikal Ltd announcements